Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15300153 | 0.97 | FAAH (0.32) | FAAHGPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL7364983 | 0.78 | CHRM2 (0.32) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL3794730 | 0.71 | — | — | |
| SCHEMBL31544790 | 0.70 | GPR119 (0.33) | FAAHGPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL19892750 | 0.69 | CHRM2 (0.34) | GPR119CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL22324901 | 0.68 | CHRM2 (0.33) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL28107442 | 0.67 | USP2 (0.37) | GPR119CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL28428311 | 0.67 | CHRM2 (0.39) | GPR119CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL30121408 | 0.66 | CHRM2 (0.34) | GPR119CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL5879706 | 0.66 | CHRNB2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | FAAH 399/4885GPR119 306/4885CHRM2 1121/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | FAAH 265/4885GPR119 355/4885CHRM2 1508/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | FAAH 278/4885GPR119 205/4885CHRM2 1690/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | FAAH 1226/4885GPR119 302/4885CHRM2 2227/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | FAAH 1646/4885GPR119 356/4885CHRM2 1276/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | FAAH 1226/4885GPR119 302/4885CHRM2 2227/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | FAAH 1646/4885GPR119 356/4885CHRM2 1276/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | FAAH 278/4885GPR119 205/4885CHRM2 1690/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | FAAH 1275/4885GPR119 116/4885CHRM2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.